Table 3.

Predictive value of mutation status

		KRAS, BRAF, or NRAS mutation present			KRAS, BRAF, and NRAS mutation absent			Nominal interaction p value	Adjusted interaction p value*
		Standard-of- care group (n=22)	Trametinib group (n=22)	HR or OR (95% CI)	Standard-of-care group (n=42)	Trametinib group (n=48)	HR or OR (95% CI)
Progression-free survival		..	..	..	..	..	..	0·72	0·72
	Number of events	20	20	..	38	37	..	..	..
	Median progression-free survival, months (95% CI)	11·4 (3·7–13·3)	13·2 (9·4–20·8)	HR 0·55 (0·28–1·07)	6·3 (3·7–9·9)	7·3 (5·6–12·7)	HR 0·64 (0·39–1·03)	..	..
Clinical response		..	..	..	..	..	..	0·054	0·11
	Number of participants with a complete or partial response	2	11	..	3	4	..	..	..
	Overall response rate (95% CI)	9·1% (1·9–26·1)	50·0% (30·2–69·8)	OR 10·17 (1·89–54·65)	7·1% (2·1–17·9)	8·3% (2·9–18·6)	OR 1·13 (0·26–4·79)	..	..

HR=hazard ratio. OR=odds ratio.

^*Adjusted for multiple comparisons.